查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1924678

注射用高免疫球蛋白市場依適應症、給藥途徑、包裝、最終用戶、通路和應用分類－2026-2032年全球預測

Hyperimmune Globulin Injection Market by Indication, Route Of Administration, Packaging Type, End User, Distribution Channel, Application - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，高免疫球蛋白注射劑市場價值將達到 13.2 億美元，到 2026 年將成長至 14.4 億美元，到 2032 年將達到 26.1 億美元，年複合成長率為 10.21%。

關鍵市場統計數據
基準年 2025 13.2億美元
預計年份：2026年 14.4億美元
預測年份 2032 26.1億美元
複合年成長率 (%) 10.21%

高免疫球蛋白注射液概述：涵蓋臨床應用、生產關鍵點以及醫療機構中相關人員的考慮因素

高免疫球蛋白注射劑是一種成熟的免疫療法，用於在多種臨床情況下提供被動免疫。這些產品由含有高效價特異性抗體的混合血漿製成，可用於預防和治療，降低感染疾病的風險並治療毒素介導的疾病。臨床醫生和採購團隊重視其靶向中和活性和明確的臨床應用案例，而生產商和監管機構則強調供體篩檢、抗體效力和一致的生產控制，以確保其安全性和有效性。

從技術、監管和醫療服務角度來看，正在塑造高免疫球蛋白注射模式的關鍵變革

受科學進步、供應鏈現代化以及監管機構對產品一致性日益重視的推動，高免疫球蛋白注射劑的市場環境正經歷著多項變革。供體篩檢和抗體滴度測定技術的進步使得血漿樣本的選擇更加精準，從而改善了效價譜並降低了批次差異。同時，分離和病毒去活化技術的創新提高了產品的安全裕度，而模組化生產方式則有助於應對突發的需求。

評估2025年美國關稅變化對血漿衍生治療藥物供應鏈韌性、籌資策略和分銷經濟性的累積影響

2025年實施的關稅調整和貿易措施為本已複雜的血漿衍生治療藥物供應鏈帶來了新的挑戰。關稅調整影響跨境血漿採購的經濟效益、中間成分的流通以及成品生物製品的進口。這促使相關人員重新評估其籌資策略，優先考慮與地理分散的供應商建立合作關係，並考慮實施國內生產或區域供應模式，以減少海關相關的延誤和成本波動。

詳細的細分市場分析揭示了適應症、用途、給藥途徑、最終用戶複雜性、通路和包裝形式如何共同影響臨床和營運決策。

細分市場層面的洞察揭示了臨床應用、給藥途徑、終端用戶特徵和包裝形式如何相互作用，從而影響需求模式和營運優先順序。根據適應症的不同，白喉、乙型肝炎、狂犬病、呼吸道融合細胞病毒和破傷風等疾病的產品關鍵性各不相同，每種臨床場景都對給藥時間和效力提出了獨特的要求，從而影響庫存管理和臨床通訊協定。在基於用途的分類中，預防性用藥和治療性用藥的區別會影響給藥頻率、獲取的緊迫性以及支付方的考慮。預防性用藥方案強調可預測的供應，而治療性用藥則需要快速取得，以滿足急性照護需求。

美洲、歐洲、中東和非洲以及亞太地區的區域趨勢和結構差異將影響高免疫療法的供應、監管和臨床應用。

區域趨勢正在影響美洲、歐洲、中東和非洲以及亞太地區的供應鏈、監管參與和應用模式。雖然美洲地區完善的血漿採集基礎設施和一體化生產網路能夠保障不間斷的生產，但公立和私立醫療機構的區域需求模式和報銷環境卻存在差異。因此，美洲地區的相關人員往往致力於最佳化捐贈者招募策略和配送物流，以滿足都市區遍遠地區的醫療需求。

競爭格局分析，重點在於闡述血漿分餾公司、特種生技藥品公司、契約製造和分銷合作夥伴之間的策略差異化因素。

高免疫球蛋白領域的競爭動態反映了由血漿分餾公司、特種生技藥品公司、契約製造和經銷商組成的複雜生態系統。領先企業通常透過投資強大的捐血網路、檢驗的病毒去活化平台以及用於抗體滴度表徵的先進分析技術來實現差異化。此外，能夠整合從血漿採集到最終灌裝和包裝的端到端能力的公司往往能夠更好地控制可追溯性和批次一致性。同時，專注於特定臨床適應症的公司能夠與醫療機構和公共衛生組織主導策略聯盟。

為製造商、經銷商和醫療保健提供者提供切實可行的建議，以增強韌性、調整臨床准入並最佳化商業性執行。

產業領導者應採取一系列務實且優先的措施，以提高供應可靠性、臨床可及性和商業性可行性。首先，透過將國內捐贈者計畫與精心挑選的國際供應商結合，建構血漿來源冗餘，同時透過投資於捐贈者維繫和抗體滴度最佳化，確保高品質的原料。其次，透過檢驗可靠的病毒去活化技術、加強批次級分析以及實施數位化品質體系，實現生產流程現代化，從而提高可追溯性並縮短產品放行週期。第三，使產品包裝策略與醫療服務實際情況相符。評估多管瓶和單劑量管瓶包裝方案在預期給藥環境下的適用性，以減少廢棄物並簡化物流。

我們採用混合方法研究，結合關鍵相關人員訪談、二手技術審查和迭代同行檢驗，以確保研究結果的嚴謹性和透明度。

本調查方法採用混合方法，結合一手質性訪談、系統性二手文獻綜述和技術檢驗，以確保研究結果的實證性。一手研究包括對臨床專家、生產品質經理、採購負責人和物流經理進行結構化訪談，以了解實際營運中的限制因素、臨床決策促進因素以及供應商談判趨勢。二級資訊來源包括同行評審的臨床文獻、監管指導文件、生產最佳實踐標準以及公開的臨床項目描述，用於闡釋訪談結果並檢驗技術論點。

針對參與高免疫球蛋白治療的相關人員，綜合考慮臨床重要性、營運要務和供應鏈韌性因素，得出策略性結論。

總之，高免疫球蛋白注射劑在現代治療手段中佔有重要的策略地位，它透過特異性抗體提供標靶被動免疫，進而發揮臨床療效。血漿選擇和分離技術的進步、改變給藥途徑的醫療服務模式的演變以及監管機構對可追溯性的重視，正在共同重塑相關人員的優先事項。供應鏈韌性仍然是一項核心挑戰，因為關稅變化和區域基礎設施差異凸顯了多元化採購、區域生產策略和更強大的物流夥伴關係關係的重要性。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 依適應症分類的高免疫球蛋白注射市場

  • 白喉
  • B型肝炎
  • 狂犬病
  • 呼吸道融合細胞病毒
  • 破傷風

9. 依給藥途徑分類的高免疫球蛋白注射劑市場

  • 肌肉內注射
  • 靜脈注射

第10章 高免疫球蛋白注射液市場（依包裝類型分類）

  • 多劑量管瓶
  • 單劑量管瓶

第11章 以最終用戶分類的高免疫球蛋白注射劑市場

  • 門診治療中心
  • 診所
  • 家庭醫療保健
  • 醫院
    • 私立醫院
    • 公立醫院

第12章 高免疫球蛋白注射劑市場（依通路分類）

  • 離線
  • 線上

第13章 高免疫球蛋白注射劑市場依應用領域分類

  • 預防
  • 治療

第14章 各地區高免疫球蛋白注射市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章 高免疫球蛋白注射劑市場（依組別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 各國高免疫球蛋白注射劑市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章：美國高免疫球蛋白注射市場

第18章：中國高免疫球蛋白注射劑市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • ADMA Biologics
  • Baxter International Inc.
  • Bharat Serums and Vaccines Limited
  • Bio Products Laboratory
  • Biotest AG
  • China Biologic Products Holdings, Inc.
  • CSL Behring
  • Emergent BioSolutions
  • Green Cross Corporation
  • Grifols
  • Hualan Biological Engineering Inc.
  • Intas Pharmaceuticals Ltd.
  • Kamada Pharmaceuticals
  • Kedrion Biopharma
  • LFB Group
  • Octapharma
  • Sanquin
  • Shanghai RAAS Blood Products Co., Ltd.
  • Shire
  • Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.
Product Code: MRR-7A380DA7C41C

The Hyperimmune Globulin Injection Market was valued at USD 1.32 billion in 2025 and is projected to grow to USD 1.44 billion in 2026, with a CAGR of 10.21%, reaching USD 2.61 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.32 billion
Estimated Year [2026] USD 1.44 billion
Forecast Year [2032] USD 2.61 billion
CAGR (%) 10.21%

Foundational overview of hyperimmune globulin injections covering clinical roles, manufacturing imperatives, and stakeholder considerations across healthcare settings

Hyperimmune globulin injections represent an established immunotherapy modality used to confer passive immunity in diverse clinical contexts. These products, derived from pooled plasma with high titers of specific antibodies, are applied across prophylactic and therapeutic indications to mitigate infectious disease risk and treat toxin-mediated conditions. Clinicians and procurement teams value their targeted neutralizing activity and defined clinical use cases, while manufacturers and regulators focus on donor screening, antibody potency, and consistent manufacturing controls to ensure safety and efficacy.

The manufacturing pathway for hyperimmune globulins integrates plasma collection, fractionation, plasma testing, virus inactivation/removal steps, and final formulation under stringent quality systems. As a result, supply reliability depends on robust plasma sourcing networks, capacity for validated viral clearance technologies, and facility compliance with current Good Manufacturing Practice. From a clinical perspective, therapeutic choice and administration hinge on indication specificity, route of administration, and patient comorbidity profiles. Consequently, stakeholders must balance clinical guidelines, logistical constraints, and evolving regulatory expectations when integrating hyperimmune globulin injections into care pathways.

Key transformative shifts shaping the hyperimmune globulin injection landscape from technological, regulatory, and care delivery perspectives

The landscape for hyperimmune globulin injections is undergoing several transformative shifts driven by scientific advances, supply chain modernization, and regulatory emphasis on product consistency. Advances in donor screening and antibody titering enable more precise selection of plasma units, improving potency profiles and reducing variability between production lots. At the same time, innovations in fractionation and viral inactivation technologies strengthen product safety margins, while modular manufacturing approaches support scalable responses to episodic demand.

Concurrently, health systems are recalibrating care delivery models that affect where and how hyperimmune globulins are administered, pushing some administrations toward ambulatory and home settings while hospitals preserve capacity for acute and complex treatments. Additionally, heightened regulatory scrutiny around traceability and batch-to-batch comparability has encouraged manufacturers to invest in enhanced quality control platforms and digital documentation systems. Taken together, these shifts raise expectations for predictable supply, clinical clarity of indication, and improved time-to-treatment workflows across the continuum of care.

Assessment of the cumulative implications of United States tariff revisions in 2025 on supply chain resilience, sourcing strategies, and distribution economics for plasma-derived therapeutics

The implementation of revised tariffs and trade measures in 2025 has layered new considerations onto an already complex supply chain for plasma-derived therapies. Tariff adjustments influence the economics of cross-border plasma procurement, movement of intermediary components, and the importation of finished biologic products. In practice, this drives stakeholders to reassess sourcing strategies, prioritize geographically diversified supplier relationships, and explore onshore manufacturing or regionalized supply models to mitigate customs-related delays and cost volatility.

Moreover, tariff-driven cost pressures prompt manufacturers and distributors to examine their logistics footprints, optimize inventory policies, and renegotiate contractual terms with suppliers and payers. Health systems and payers respond by scrutinizing procurement frameworks and considering alternative distribution pathways to preserve clinical access. While tariffs do not change clinical indications or scientific rationale for use, they do affect the affordability and accessibility calculus for institutions, especially those that rely heavily on imported products or centralized manufacturing located outside their region.

In-depth segmentation insights revealing how indication, application, administration route, end user complexity, distribution channel, and packaging format jointly influence clinical and operational decisions

Segment-level insights reveal how clinical application, administration route, end user dynamics, and packaging format interact to shape demand patterns and operational priorities. Based on indication, product relevance varies across diphtheria, hepatitis B, rabies, respiratory syncytial virus, and tetanus, with each clinical scenario imposing distinct timing and potency requirements that inform inventory management and clinical protocols. Based on application, the differentiation between prophylactic and therapeutic use influences dosing frequency, urgency of access, and payer considerations, with prophylactic programs emphasizing predictable supply and therapeutic use requiring rapid availability for acute care.

Based on route of administration, intramuscular and intravenous delivery pose divergent training, storage, and administration workflows; intramuscular injections typically align with outpatient and ambulatory settings, whereas intravenous administration concentrates demand in inpatient or specialized infusion sites. Based on end user, the granular heterogeneity among ambulatory care centers, clinics, home healthcare, and hospitals-and the further subdivisions such as physician offices and urgent care within ambulatory care centers, general and specialty clinics, home infusion and home nursing within home healthcare, and private and public hospitals-creates differentiated procurement cycles, cold chain needs, and billing pathways. Based on distribution channel, hospital pharmacy, online pharmacy, and retail pharmacy each present distinct regulatory, dispensing, and logistics profiles that influence how products reach patients. Finally, based on packaging type, the choice between multi dose vial and single dose vial affects inventory turnover, wastage risk, and cold-chain handling protocols.

Regional dynamics and structural variations across the Americas, Europe, Middle East & Africa, and Asia-Pacific that influence supply, regulation, and clinical adoption of hyperimmune therapies

Regional dynamics shape supply chains, regulatory engagement, and adoption patterns across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, established plasma collection infrastructures and integrated manufacturing networks support uninterrupted production, yet regional demand patterns and reimbursement environments differ between public and private healthcare providers. Consequently, stakeholders in the Americas often focus on optimizing donor recruitment strategies and distribution logistics to meet both urban and rural access needs.

Across Europe, Middle East & Africa, regulatory harmonization efforts coexist with heterogeneous reimbursement systems and variable plasma sourcing capacity, prompting manufacturers to build flexible distribution networks and engage in targeted regulatory dialogue. In the Asia-Pacific region, rapid healthcare modernization, expanding ambulatory care capacity, and growing emphasis on local manufacturing investments are reshaping where and how hyperimmune globulins are produced and delivered. These regional trends influence partnership models, clinical adoption timelines, and the prioritization of investments in cold chain infrastructure and local regulatory support.

Competitive landscape intelligence highlighting the strategic differentiators among plasma fractionators, specialty biologics producers, contract manufacturers, and distribution partners

Competitive dynamics in the hyperimmune globulin space reflect a mix of plasma fractionators, specialty biologics manufacturers, contract manufacturing organizations, and distributors that together form a complex ecosystem. Leading players often differentiate through investments in donor network strength, validated viral inactivation platforms, and advanced analytics for antibody titer characterization. In addition, companies that integrate end-to-end capabilities-from plasma procurement to final fill-finish-tend to achieve greater control over traceability and lot consistency, while firms that specialize in niche clinical indications can command strategic partnerships with healthcare providers and public health agencies.

Collaboration between manufacturers and specialized logistics providers is increasingly important to maintain cold chain integrity and rapid distribution. Strategic alliances, licensing agreements, and targeted acquisitions are common mechanisms used to expand capacity, enter new geographic markets, or accelerate time-to-market for indication-specific products. At the same time, firms that cultivate strong regulatory expertise and transparent pharmacovigilance frameworks create competitive advantages in procurement negotiations and clinical adoption discussions with hospitals and payers.

Actionable recommendations for manufacturers, distributors, and healthcare providers to enhance resilience, align clinical access, and optimize commercial execution

Industry leaders should adopt a set of pragmatic, prioritized actions to strengthen supply reliability, clinical accessibility, and commercial viability. First, build redundancy in plasma sourcing by cultivating a mix of domestic donor programs and selective international suppliers, while investing in donor retention and antibody titer optimization to secure higher-quality input material. Second, modernize manufacturing practices by validating robust viral reduction technologies, enhancing batch-level analytics, and implementing digital quality systems that improve traceability and reduce release cycle times. Third, align product packaging strategy with care delivery realities by evaluating multi dose vial and single dose vial configurations against expected administration settings to reduce wastage and streamline logistics.

Additionally, engage proactively with payers and clinical leaders to clarify appropriate prophylactic versus therapeutic use cases and to design pragmatic access pathways for ambulatory and home healthcare settings. Finally, pursue strategic partnerships with specialized logistics and regional manufacturing partners to offset tariff exposure and to accelerate regional regulatory approvals. These steps, taken together, will improve resilience, lower operational friction, and strengthen the position of stakeholders across the value chain.

Mixed-methods research approach combining primary stakeholder interviews, secondary technical review, and iterative expert validation to ensure rigorous, transparent insights

The research methodology integrates a mixed-methods approach combining primary qualitative interviews, systematic secondary literature review, and technical validation to ensure robust and defensible findings. Primary research included structured interviews with clinical specialists, manufacturing quality leaders, procurement officers, and logistics executives to capture real-world operational constraints, clinical decision drivers, and supplier negotiation dynamics. Secondary sources comprised peer-reviewed clinical literature, regulatory guidance documents, manufacturing best-practice standards, and public clinical program descriptions to contextualize interview insights and corroborate technical assertions.

Data synthesis relied on cross-validation across information streams and iterative expert review to reconcile conflicting inputs. Technical validation of manufacturing and quality assertions was achieved through anonymized supplier disclosures and regulatory inspection summaries. Throughout the process, emphasis was placed on transparency of assumptions, traceability of qualitative inputs, and clarity around limitations, ensuring that conclusions reflect observable industry practice without extrapolating beyond validated evidence.

Strategic conclusion synthesizing clinical importance, operational imperatives, and supply chain resilience considerations for stakeholders engaged with hyperimmune globulin therapies

In summary, hyperimmune globulin injections occupy a strategic niche in modern therapeutic arsenals, delivering targeted passive immunity where specific antibodies provide clinical benefit. The interplay of technological improvements in plasma selection and fractionation, evolving care delivery models that shift administration venues, and regulatory emphasis on traceability are collectively reshaping stakeholder priorities. Supply chain resilience remains central, with tariff changes and regional infrastructure differences reinforcing the need for diversified sourcing, regional manufacturing strategies, and stronger logistics partnerships.

As clinical programs continue to refine indication-specific protocols and as manufacturers invest in quality and analytics, organizations that proactively align operational capability with clinical and payer expectations will achieve more predictable access and better patient outcomes. Ultimately, the path forward favors integrated strategies that combine technical excellence, pragmatic distribution planning, and collaborative engagement with clinical and regulatory stakeholders.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Hyperimmune Globulin Injection Market, by Indication

  • 8.1. Diphtheria
  • 8.2. Hepatitis B
  • 8.3. Rabies
  • 8.4. Respiratory Syncytial Virus
  • 8.5. Tetanus

9. Hyperimmune Globulin Injection Market, by Route Of Administration

  • 9.1. Intramuscular
  • 9.2. Intravenous

10. Hyperimmune Globulin Injection Market, by Packaging Type

  • 10.1. Multi Dose Vial
  • 10.2. Single Dose Vial

11. Hyperimmune Globulin Injection Market, by End User

  • 11.1. Ambulatory Care Centers
  • 11.2. Clinics
  • 11.3. Home Healthcare
  • 11.4. Hospitals
    • 11.4.1. Private Hospitals
    • 11.4.2. Public Hospitals

12. Hyperimmune Globulin Injection Market, by Distribution Channel

  • 12.1. Offline
  • 12.2. Online

13. Hyperimmune Globulin Injection Market, by Application

  • 13.1. Prophylactic
  • 13.2. Therapeutic

14. Hyperimmune Globulin Injection Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Hyperimmune Globulin Injection Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Hyperimmune Globulin Injection Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Hyperimmune Globulin Injection Market

18. China Hyperimmune Globulin Injection Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. ADMA Biologics
  • 19.6. Baxter International Inc.
  • 19.7. Bharat Serums and Vaccines Limited
  • 19.8. Bio Products Laboratory
  • 19.9. Biotest AG
  • 19.10. China Biologic Products Holdings, Inc.
  • 19.11. CSL Behring
  • 19.12. Emergent BioSolutions
  • 19.13. Green Cross Corporation
  • 19.14. Grifols
  • 19.15. Hualan Biological Engineering Inc.
  • 19.16. Intas Pharmaceuticals Ltd.
  • 19.17. Kamada Pharmaceuticals
  • 19.18. Kedrion Biopharma
  • 19.19. LFB Group
  • 19.20. Octapharma
  • 19.21. Sanquin
  • 19.22. Shanghai RAAS Blood Products Co., Ltd.
  • 19.23. Shire
  • 19.24. Sichuan Yuanda Shuyang Pharmaceutical Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY PACKAGING TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY DIPHTHERIA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY DIPHTHERIA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY DIPHTHERIA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY HEPATITIS B, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY HEPATITIS B, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY HEPATITIS B, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY RABIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY RABIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY RABIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY RESPIRATORY SYNCYTIAL VIRUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY RESPIRATORY SYNCYTIAL VIRUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY RESPIRATORY SYNCYTIAL VIRUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY TETANUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY TETANUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY TETANUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY MULTI DOSE VIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY MULTI DOSE VIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY MULTI DOSE VIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY SINGLE DOSE VIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY SINGLE DOSE VIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY SINGLE DOSE VIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY AMBULATORY CARE CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY AMBULATORY CARE CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY PRIVATE HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY PRIVATE HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY PRIVATE HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY PUBLIC HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY PUBLIC HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY PUBLIC HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY PROPHYLACTIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY PROPHYLACTIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY PROPHYLACTIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY THERAPEUTIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY THERAPEUTIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY THERAPEUTIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. AMERICAS HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 68. AMERICAS HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 69. AMERICAS HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 70. AMERICAS HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 71. AMERICAS HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 72. AMERICAS HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 73. AMERICAS HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 75. NORTH AMERICA HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 77. NORTH AMERICA HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 78. NORTH AMERICA HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 80. NORTH AMERICA HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 83. LATIN AMERICA HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. LATIN AMERICA HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 85. LATIN AMERICA HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 87. LATIN AMERICA HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 88. LATIN AMERICA HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE, MIDDLE EAST & AFRICA HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE, MIDDLE EAST & AFRICA HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE, MIDDLE EAST & AFRICA HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE, MIDDLE EAST & AFRICA HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE, MIDDLE EAST & AFRICA HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE, MIDDLE EAST & AFRICA HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE, MIDDLE EAST & AFRICA HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 107. MIDDLE EAST HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. MIDDLE EAST HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 109. MIDDLE EAST HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 110. MIDDLE EAST HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. MIDDLE EAST HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 112. MIDDLE EAST HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 113. MIDDLE EAST HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 114. MIDDLE EAST HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 115. AFRICA HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. AFRICA HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 117. AFRICA HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 118. AFRICA HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. AFRICA HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 120. AFRICA HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 121. AFRICA HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 122. AFRICA HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. ASEAN HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. ASEAN HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 134. ASEAN HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 135. ASEAN HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. ASEAN HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. ASEAN HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 138. ASEAN HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 139. ASEAN HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 140. GCC HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. GCC HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 142. GCC HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 143. GCC HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. GCC HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 145. GCC HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 146. GCC HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 147. GCC HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPEAN UNION HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPEAN UNION HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPEAN UNION HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPEAN UNION HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPEAN UNION HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPEAN UNION HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPEAN UNION HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPEAN UNION HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 156. BRICS HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. BRICS HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 158. BRICS HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 159. BRICS HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. BRICS HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 161. BRICS HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 162. BRICS HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 163. BRICS HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 164. G7 HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. G7 HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 166. G7 HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 167. G7 HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. G7 HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 169. G7 HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 170. G7 HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 171. G7 HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 172. NATO HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 173. NATO HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 174. NATO HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 175. NATO HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. NATO HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 177. NATO HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 178. NATO HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 179. NATO HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 180. GLOBAL HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. UNITED STATES HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 182. UNITED STATES HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 183. UNITED STATES HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 184. UNITED STATES HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. UNITED STATES HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 186. UNITED STATES HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 187. UNITED STATES HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 188. UNITED STATES HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 189. CHINA HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 190. CHINA HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 191. CHINA HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 192. CHINA HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY PACKAGING TYPE, 2018-2032 (USD MILLION)
  • TABLE 193. CHINA HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 194. CHINA HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY HOSPITALS, 2018-2032 (USD MILLION)
  • TABLE 195. CHINA HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 196. CHINA HYPERIMMUNE GLOBULIN INJECTION MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)